Actavis' Viberzi, Valeant's Xifaxan OK'd in IBS-D in US
This article was originally published in Scrip
The FDA on 27 May approved Actavis' and Patheon Pharmaceuticals' Viberzi (eluxadoline) and Valeant's and its subsidiary Salix's Xifaxan (rifaximin) to treat adults with irritable bowel syndrome with diarrhea (IBS-D).
You may also be interested in...
Allergan PLC has $27.6m in cash after closing the $40.5bn sale of its generics business to Teva Pharmaceutical Industries Ltd. and paying down $9.3bn debt, but the company will rely on blockbuster sales gains and recent launches for revenue and earnings growth, not a big acquisition.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.